Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
It is the first autotaxin inhibitor to be investigated in cancer patients
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Subscribe To Our Newsletter & Stay Updated
